血清Adropin与急性非ST段抬高型急性冠脉综合征患者冠状动脉病变严重程度及慢血流的相关性研究

背景　目前，冠状动脉病变的严重程度主要根据有创的SYNTAX评分进行评估，经皮冠状动脉介入治疗（PCI）术中是否出现慢血流更是难以预测。能否在无创的前提下找到一种生物标志物来准确预测高危冠状动脉病变及慢血流现象的发生，已经成为心血管研究热点之一。目的　评价急性非ST段抬高型急性冠脉综合征（NSTE-ACS）患者血清Adropin与冠状动脉病变严重程度及PCI术中出现慢血流的关系。方法　选取2016年3月-2018年6月广州医科大学附属第三医院因NSTE-ACS入院行PCI术患者240例，另选取同期心内科40例冠状动脉造影正常者作为对照组。NSTE-ACS患者进行SYNTAX评分，根据SYNTAX评分分为：高危组（SYNTAX≥33分）、中危组（22分

Associations of Serum Adropin Level with Severity of Coronary Artery Disease and Slow Flow in Patients with Non-ST-elevation ACS

Background　At present，the severity of coronary artery lesions is mainly assessed by invasive coronary angiography-based SYNTAX score，and it is hard to predict slow flow during PCI.Finding a biomarker to accurately predict high-risk coronary lesions and the occurrence of slow flow has become one of the hot spots in cardiovascular research.Objective　The present study is an analysis of the relationship of serum Adropin level with the severity of coronary artery disease （CAD） as well as slow flow during PCI in patients with non-ST-elevation acute coronary syndrome （NSTE-ACS）.Methods　A total of 280 participants，240 with NSTE-ACS underwent PCI and 40 individuals with normal coronary angiography （control group） were prospectively enrolled during March 2016 to June 2018.According to the SYNTAX score，patients with NSTE-ACS were divided to high-risk subgroup （SYNTAX score≥33），medium-risk subgroup （22